Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-Reference-Cited by-同舟云学术

Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

Published:2024-05-30 Issue: Volume: Page:
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:

Author:

Nakayama Yoichi¹^ORCID,Nagata Wataru²,Takeuchi Yoichi³,Fukui Sho⁴,Fujita Yuya⁵,Hosokawa Yohei⁶,Ueno Masanobu⁵,Ono Kumiko⁷,Sumitomo Shuji⁸,Tabuchi Yuya¹,Nakanishi Yuichiro⁹,Saito Shuntaro¹⁰,Ikeuchi Hiroko¹¹,Kawamori Kazutaka¹²,Sofue Hideaki⁹,Doi Goro¹³,Minami Runa¹⁴,Hirota Tomoya¹⁵,Minegishi Kaoru¹⁶,Maeshima Keisuke¹⁷,Motoyama Ryo¹⁸,Nakamura Shohei¹⁸,Suzuki Shotaro¹⁹,Nishioka Norihiro¹¹,Wada Takuma Tsuzuki²⁰,Onishi Akira²¹,Nishimura Kenichi²²,Watanabe Ryu²³,Yanai Ryo¹²,Kida Takashi⁹,Nishiwaki Hiroki²⁴,Yajima Nobuyuki¹²,Kaneko Yuko¹⁰,Tanaka Eiichi¹⁸,Kawahito Yutaka⁹,Harigai Masayoshi¹⁸^ORCID

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto, Japan

2. Department of Pharmacology, National Defense Medical College , Tokorozawa, Japan

3. Department of Rheumatology and Nephrology, Japanese Red Cross Maebashi Hospital , Maebashi, Japan

4. Department of Emergency and General Medicine, Kyorin University School of Medicine , Tokyo, Japan

5. The First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu, Japan

6. Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima, Japan

7. Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo , Tokyo, Japan

8. Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe, Japan

9. Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan

10. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan

11. Department of Preventive Services, School of Public Health, Graduate School of Medicine and Faculty of Medicine, Kyoto University , Kyoto, Japan

12. Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo, Japan

13. Department of Internal Medicine, Kyushu University Beppu Hospital , Oita, Japan

14. Department of Orthopaedic Surgery and Rheumatology, Otokoyama Hospital , Kyoto, Japan

15. Department of Infection and Rheumatology, University of Fukui Hospital , Fukui, Japan

16. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan

17. Department of Rheumatology, Nishida Hospital , Saiki, Japan

18. Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine , Tokyo, Japan

19. Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine , Kawasaki, Japan

20. Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University , Saitama, Japan

21. Department of Advanced Medicine of Rheumatic Diseases, Graduate School of Medicine, Kyoto University , Kyoto, Japan

22. Department of Pediatrics, Yokohama City University Graduate School of Medicine , Yokohama, Japan

23. Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka, Japan

24. Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital , Yokohama, Japan

Abstract

ABSTRACT Objectives The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA). Methods We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses. Results Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naïve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (csDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients. Conclusions This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/mr/advance-article-pdf/doi/10.1093/mr/roae049/58994308/roae049.pdf

Reference108 articles.

1. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study;Cross;Ann Rheum Dis,2014

2. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study;Sokka;Arthritis Res Ther,2010

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update;Smolen;Ann Rheum Dis,2023

4. Guidelines for the management of rheumatoid arthritis (in Japanese);Kawahito;Nihon Rinsho,2016